Lung Cancer Drug Development: Prolonging Life v. Treating Symptoms
This article was originally published in Pharmaceutical Approvals Monthly
FDA’s next patient-focused drug development meeting will ask what’s most important when diagnosed with a disease that has a median survival time of a little over a year.
You may also be interested in...
Broader Indications For Tarceva As Astellas Scales Back In The U.S.
The Japanese pharma is consolidating its U.S. operations, including the shuttering of OSI, where Tarceva initially was developed, as the cancer drug gains another indication with a companion diagnostic.
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
Biomarker-guided targeted therapy has become a standard approach to oncology R&D, but few new targeted drugs have reached the market for lung cancer. A new wave of research could change that, and improve the outlook for lung cancer treatment.
Teva’s ‘Skinny Label’ Dispute Edges Toward Supreme Court With Government’s Backing
US Solicitor General urges the Supreme Court to grant Teva's petition, arguing that the Federal Circuit was wrong in ruling that Teva's carved-out labeling for generic carvedilol induced infringement of GlaxoSmithKine's brand product.